IDENTIFICATION MARKERS OF INFECTION DUE TO C. TRACHOMATIS AND C. PNEUMONIAE, IN PATIENTS WITH DISEASES OF THE GASTROINTESTINAL TRACT

To date, clinical data have convincingly shown that C. trachomatis and C. pneumoniae infectious can cause serious diseases with severe complications and consequences. There are assumptions that the developed chronic chlamydial infection can become an important factor in the pathogenesis of the gastrointestinal tract diseases, which are manifested in the so-called post-infectious period. It is commonly known that chlamydial infection has a tropism to the cylindrical epithelium, which covers the human mucous membrane of the urethra, cervix, rectum, conjunctiva of the eyes and the throat. However, the role of the causative agents of chlamydial infections, such as C. trachomatis and C. pneumoniae, in the occurrence of the gastrointestinal tract diseases has not been studied. In order to study the possible relationship between the gastrointestinal diseases and the presence of chlamydial infection markers, we have selected a group of patients with the gastrointestinal diseases and detected antibodies to C. trachomatis and C. pneumoniae and DNA of these pathogens in blood serum, liver biopsy and bile ducts. As a result, C. trachomatis DNA in blood serum was detected in 50% of cases, and in liver biopsies — in 59.3%. A new approach has been developed in the serological diagnosis of chlamydial infection caused by C. trachomatis, which allowed for revealing diagnostic antibody titers in 51.9% of cases in this group of patients, and in the comparison group — in 11.6% of cases. Among 50% of patients, in whom DNA was revealed in blood serum, it was also revealed in 64.3% of cases in biopsy samples of gastrointestinal organs. Upon detection of C. trachomatis DNA in blood serum, antibodies to the “cultural” antigen were detected in 60.1% of cases, and with the simultaneous detection of C. trachomatis DNA in blood serum and gastrointestinal organs, they were found in 72.2% of cases. Simultaneous detection of C. trachomatis, both in blood serum and in the gastrointestinal tract, may indicate the ability of C. trachomatis to spread hematogenously and infect organs away from the primary focus of infection. The obtained data absolutely require further study in light of the identification of the relationship between the detection of the pathogen and the development of the gastrointestinal pathology. But in general, the results are not yet studied evidence of the possible gastrointestinal organs infection by C. trachomatis

EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA

Aim. To find the optimal scheme of lycopene application and to compare clinical efficacy of two lycopene presentations produced on the basis of 1) vegetable oil and 2) milk protein (lactolycopene) in patients with dyslipidemia.Material and methods. At the first step of the study to choice an optimal scheme of pharmacotherapy efficacy of three schemes of lycopene (lactolycopene) application was compared in three groups of patients (n= 27, 25 and 28 respectively) with ischemic heart disease, dyslipidemia and high level of lipid peroxygenation (LPO). At the second step two groups of patients (n=28 and 31) with dyslipidemia received lycopene in the same dose at the same time but in different presentations. Patients of the first group received oil solution of lycopene in capsules, patients of the second group — a powder of lactolycopene dissolved in 100 ml of boiled water. Levels of total cholesterol (TC), high density (HDC) and low density cholesterol (LDC), triglycerides (TG) and LPO activity marker, malondialdehyde (MDA), were studied. The duration of each study step was 8 weeks.Results. Lactolycopene 10 mg QD for the night was as effective as 10 mg TID (30 mg per day) in normalization of the lipid metabolism parameters and malondialdehyde level due to chronopharmacological mechanism. Similar efficacy of the evening lactolycopene reception 10 mg QD and 30 mg QD was due to the saturation of tissues with an antioxidant. Lactolycopene application led to significant reduction in levels of TC (from 247.1±27 to 186.5±12 mg/dl; p<0.001), LDC (from 150.9±17 to 119.3±8 mg/dl; p<0.001), TG (from 165.8±12 to 128±10 mg/dl; p<0.001) and MDA (from 2.67±0.2 to 1.3±0.07 nM/ml; p<0.001) unlike reception of oil solution of lycopene.Conclusion: Lactolycopene has higher effect on lipid metabolism and LPO in comparison with this in lycopene in oil solution presentation. An optimal scheme of lactolycopene reception is 10 mg for the night

Clinical cases of colonic torsions in patients with inborn anatomic variants

The clinic, diagnosis and treatment of two cases of dolichocolon torsions are represented: a women 31 and a men 34 years old. The represented clinical observations show diagnostic difficulties encountered in patients with congenital malformations of the colon